Search arXiv⌕ Search

arXiv subjects

Marko Tvrdic

Publications and source records attributed to Marko Tvrdic.

2 recordsLinked to original sources

Cross-species representation learning aligns mouse and human neural dynamics and tracks clinical drug efficacy

Preclinical models poorly predict human drug efficacy, particularly in neurological disorders. Neural activity offers a uniquely rich source of translational information because it captures high-dimensional variation in nervous-system function that can be measured in both animals and humans. However, its high dimensionality makes it difficult to distinguish conserved disease-related features from variation arising from species, recording modality and experimental context. Here, we test whether shared neural dynamics can be identified directly from electrophysiology data by learning representations organized by biological state rather than species. We develop a dual-rule contrastive learning framework that aligns corresponding mouse and human states while preserving separation between distinct phenotypes. This framework recovered conserved sensory-response structure across species and, in epilepsy, resolved distinct relationships between three mouse models and heterogeneous human patient populations. When treated animals were projected into a frozen cross-species representation, drug-induced movement towards the human-aligned healthy state retrospectively tracked known clinical efficacy across ten model-drug combinations including a disease-specific detrimental effect. The framework also identified shared disease-associated neural dynamics between Fmr1-knockout mice and human 16p11.2 copy-number variant carriers despite differences in genetic aetiology and recording modality. Together, these findings show the potential of cross-species neural representation learning to map heterogeneous human disease onto experimentally tractable preclinical states and assess whether interventions restore human-relevant circuit function.

q-bio.QM↗

CircuitATLAS: Agentic reasoning over a systems neuroscience knowledge graph for target discovery in circuitopathies

Drug discovery for neurological disease has traditionally centered on the molecules altered by disease. But the molecules that cause pathology are not necessarily the best points from which to reverse it. Here, we ask which otherwise unaltered molecular control points can be engaged to restore pathological neural circuits toward functional states. We present CircuitATLAS, a provenance-grounded systems-neuroscience knowledge graph and agentic framework for target discovery in circuitopathies. It structures literature-derived relationships across diseases, phenotypes, electrophysiology, circuits, brain regions, cell types and molecular effectors, while deliberately excluding direct disease-gene and disease-protein edges to reduce shortcut reasoning. The graph contains 3.83 million nodes and 7.66 million edges, including 5.31 million LLM-extracted relations, and incorporates structured datasets such as the Human Cell Atlas and new multimodal in vivo measurements. We then introduce an agentic workflow that reasons from measurable disease phenotypes through their circuit and cellular substrates to molecular interventions, therapeutic feasibility and clinical constraints. Finally, we introduce a human-governed in vivo lab-in-the-loop linking hypothesis generation to experimental iteration. Within this framework an agent nominated ATP1A3, the neuronal alpha3 Na+/K+-ATPase, as a control point on cortical excitability; interneuron-restricted expression of ATP1A3 abolished the beta- and gamma-band response to a focal 4-aminopyridine challenge in vivo, and the validated target was then carried into a structure-guided small-molecule campaign terminating in a defined assay to resolve the direction of modulation. CircuitATLAS thus provides a framework for discovering therapeutics based not only on what is molecularly disrupted in disease, but on what can be controlled to restore circuit function.

q-bio.QM↗